Pharmaceutical and biotech industry perspectives on optimizing patient experience and treatment adherence through subcutaneous drug delivery design

IF 15.2 1区医学 Q1 PHARMACOLOGY & PHARMACY Advanced drug delivery reviews Pub Date : 2024-04-26 DOI:10.1016/j.addr.2024.115322

Jennifer Stevenson , Rachel Poker , Johanna Schoss , Michael Campbell , Claire Everitt , Brian Holly , Nicholas Stones , Ronald J. Pettis , Manuel Sanchez-Felix

{"title":"Pharmaceutical and biotech industry perspectives on optimizing patient experience and treatment adherence through subcutaneous drug delivery design","authors":"Jennifer Stevenson , Rachel Poker , Johanna Schoss , Michael Campbell , Claire Everitt , Brian Holly , Nicholas Stones , Ronald J. Pettis , Manuel Sanchez-Felix","doi":"10.1016/j.addr.2024.115322","DOIUrl":null,"url":null,"abstract":"<div><p>Subcutaneous (SC) drug delivery can be a safe, effective alternative to the traditional intravenous route of administration, potentially offering notable advantages for both patients and healthcare providers. The SC Drug Development & Delivery Consortium convened in 2018 to raise awareness of industry challenges to advance the development of patient-centric SC drug delivery strategies. The SC Consortium identified better understanding of patient preferences and perspectives as necessary to optimize SC product design attributes and help guide design decisions during SC product development. This manuscript provides a comprehensive overview of patient-centric factors for consideration in the SC drug delivery design and development process with the aim of establishing a foundation of existing knowledge for patient experiences related to SC drug delivery. This overview is informed by the outcomes of a multi-step survey of Consortium members and key pharmaceutical stakeholders. Framed in the context of the patient’s treatment journey, the survey findings offer future perspectives to fill data gaps to advance patient-centric SC drug delivery.</p></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":null,"pages":null},"PeriodicalIF":15.2000,"publicationDate":"2024-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced drug delivery reviews","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0169409X24001443","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Subcutaneous (SC) drug delivery can be a safe, effective alternative to the traditional intravenous route of administration, potentially offering notable advantages for both patients and healthcare providers. The SC Drug Development & Delivery Consortium convened in 2018 to raise awareness of industry challenges to advance the development of patient-centric SC drug delivery strategies. The SC Consortium identified better understanding of patient preferences and perspectives as necessary to optimize SC product design attributes and help guide design decisions during SC product development. This manuscript provides a comprehensive overview of patient-centric factors for consideration in the SC drug delivery design and development process with the aim of establishing a foundation of existing knowledge for patient experiences related to SC drug delivery. This overview is informed by the outcomes of a multi-step survey of Consortium members and key pharmaceutical stakeholders. Framed in the context of the patient’s treatment journey, the survey findings offer future perspectives to fill data gaps to advance patient-centric SC drug delivery.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

制药和生物技术行业对通过皮下给药设计优化患者体验和治疗依从性的看法。

皮下（SC）给药是传统静脉给药途径的一种安全、有效的替代方式，可能为患者和医疗服务提供者带来显著优势。皮下给药联盟于 2018 年召开会议，旨在提高对行业挑战的认识，推动以患者为中心的皮下给药战略的发展。SC联盟认为，更好地了解患者的偏好和观点是优化SC产品设计属性的必要条件，有助于指导SC产品开发过程中的设计决策。本手稿全面概述了SC给药设计和开发过程中需要考虑的以患者为中心的因素，旨在为现有的与SC给药相关的患者体验知识奠定基础。该概述参考了对联盟成员和主要制药利益相关者进行的多步骤调查的结果。调查结果以患者的治疗历程为背景，提供了未来的视角，以填补数据空白，推动以患者为中心的给药方式。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Advanced drug delivery reviews 医学-药学

CiteScore

28.10

自引率

5.00%

发文量

294

审稿时长

15.1 weeks

期刊介绍： The aim of the Journal is to provide a forum for the critical analysis of advanced drug and gene delivery systems and their applications in human and veterinary medicine. The Journal has a broad scope, covering the key issues for effective drug and gene delivery, from administration to site-specific delivery. In general, the Journal publishes review articles in a Theme Issue format. Each Theme Issue provides a comprehensive and critical examination of current and emerging research on the design and development of advanced drug and gene delivery systems and their application to experimental and clinical therapeutics. The goal is to illustrate the pivotal role of a multidisciplinary approach to modern drug delivery, encompassing the application of sound biological and physicochemical principles to the engineering of drug delivery systems to meet the therapeutic need at hand. Importantly the Editorial Team of ADDR asks that the authors effectively window the extensive volume of literature, pick the important contributions and explain their importance, produce a forward looking identification of the challenges facing the field and produce a Conclusions section with expert recommendations to address the issues.

期刊最新文献

Editorial Board Application of MIDD to accelerate the development of anti-infectives: Current status and future perspectives Effects of nanoparticle deformability on multiscale biotransport Editorial Board Model-informed precision dosing: State of the art and future perspectives.